114 related articles for article (PubMed ID: 28216418)
1. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
Ghoncheh M; Ziaee F; Karami M; Poorolajal J
Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
[TBL] [Abstract][Full Text] [Related]
2. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
3. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
[TBL] [Abstract][Full Text] [Related]
4. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models.
Laitman Y; Simeonov M; Keinan-Boker L; Liphshitz I; Friedman E
Genet Res (Camb); 2013 Dec; 95(6):174-7. PubMed ID: 24506973
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
8. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.
Dite GS; MacInnis RJ; Bickerstaffe A; Dowty JG; Allman R; Apicella C; Milne RL; Tsimiklis H; Phillips KA; Giles GG; Terry MB; Southey MC; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):359-65. PubMed ID: 26677205
[TBL] [Abstract][Full Text] [Related]
10. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
[TBL] [Abstract][Full Text] [Related]
12. Performance of risk prediction models in breast cancer screening among women in Cyprus.
Danladi C; Serakinci N
East Mediterr Health J; 2022 Dec; 28(12):888-895. PubMed ID: 36573569
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.
Quante AS; Whittemore AS; Shriver T; Strauch K; Terry MB
Breast Cancer Res; 2012 Nov; 14(6):R144. PubMed ID: 23127309
[TBL] [Abstract][Full Text] [Related]
14. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.
Ming C; Viassolo V; Probst-Hensch N; Chappuis PO; Dinov ID; Katapodi MC
Breast Cancer Res; 2019 Jun; 21(1):75. PubMed ID: 31221197
[TBL] [Abstract][Full Text] [Related]
15. iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management.
Collins IM; Bickerstaffe A; Ranaweera T; Maddumarachchi S; Keogh L; Emery J; Mann GB; Butow P; Weideman P; Steel E; Trainer A; Bressel M; Hopper JL; Cuzick J; Antoniou AC; Phillips KA
Breast Cancer Res Treat; 2016 Feb; 156(1):171-82. PubMed ID: 26909793
[TBL] [Abstract][Full Text] [Related]
16. Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort.
MacInnis RJ; Knight JA; Chung WK; Milne RL; Whittemore AS; Buchsbaum R; Liao Y; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; Kurian AW; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
J Natl Cancer Inst; 2021 Jun; 113(6):785-791. PubMed ID: 33301022
[TBL] [Abstract][Full Text] [Related]
17. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
Panchal SM; Ennis M; Canon S; Bordeleau LJ
BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic.
Lim GH; Borje E; Allen JC
Gland Surg; 2017 Feb; 6(1):35-42. PubMed ID: 28210550
[TBL] [Abstract][Full Text] [Related]
19. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models.
Li SX; Milne RL; Nguyen-Dumont T; Wang X; English DR; Giles GG; Southey MC; Antoniou AC; Lee A; Li S; Winship I; Hopper JL; Terry MB; MacInnis RJ
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
